FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
The recent outbreak of a drug-resistant strain of shigellosis is giving pharmacists an important role in preventing and treating the gastrointestinal disease.
Pharmacists are positioned to educate and monitor older patients who are discharged on these medications.
Since patients with Barrett’s esophagus seem to progress to cancerous stages faster than others, health care professionals might perceive that controlling acid reflux would prevent the transition.
The US Centers for Disease Control and Prevention today reported that nearly half a million Clostridium difficile infections occurred in a single year, highlighting a critical need for improved antibiotic use.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$